The guidance provides concrete information on changes and protocol deviations which may be needed in the conduct of clinical trials to deal with extraordinary situations, e.g. if trial participants need to be in self-isolation or quarantine, access to public places (including hospitals) is limited due to the risk of spreading infections, and healthcare professionals are being reallocated
View this resource Bookmark this resource
Guidance on the management of clinical trials during the COVID-19 (Coronavirus) pandemic
Published by EMA
Clinical TrialsPandemy